Superior Planning, LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

Superior Planning, LLC’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$192K	Buy	+367	New	+$188K	0.08%	169

Other funds holding VRTX

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $77.1B AUM 11.99% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Superior Planning, LLC's VRTX Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2026: 367 shares worth $192K. The stake represents 0.08% of the portfolio and ranks #169 among its holdings.

1,320 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Superior Planning, LLC held 367 shares of Vertex Pharmaceuticals worth $192K as of Q3 2026.
Vertex Pharmaceuticals was a new Superior Planning, LLC position in Q3 2026.
Vertex Pharmaceuticals made up 0.08% of Superior Planning, LLC's portfolio in Q3 2026, its #169 holding.
1,320 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.